Gene: HLA-A

3105
HLAA
major histocompatibility complex, class I, A
protein-coding
6p22.1
Ensembl:ENSG00000206503 MIM:142800 Vega:OTTHUMG00000130501 UniprotKB:P01891
NG_029217.2
PubMed
0   ANCO-SNPs
ND|AD
26   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
B2M0.921
HLA-B0.919
HLA-E0.895
PSMB80.882
PSME10.875
ANXA50.869
MYL12A0.863
HLA-C0.862
SERPINB60.859
SAT10.856

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.574
OR4F5-0.55
CALHM1-0.386
ABCC12-0.375
GABRG3-0.373
KCNB2-0.368
SLC7A4-0.367
OPRD1-0.364
MARCH4-0.36
ADRA1D-0.359

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of HLA-A mRNA"20206263
C027955aflatoxin G1aflatoxin G1 results in decreased expression of HLA-A mRNA20381597
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of HLA-A mRNA24449571
C006632arsenic trioxidearsenic trioxide results in decreased expression of HLA-A mRNA19128835
C020711beryllium sulfateberyllium sulfate results in increased expression of HLA-A mRNA16314022
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of HLA-A mRNA19619570
D004958EstradiolEstradiol results in increased expression of HLA-A mRNA19619570|2118537
C111827brinzolamidebrinzolamide affects the expression of HLA-A mRNA25811541
D016642BupropionBupropion affects the expression of HLA-A mRNA25811541
C018475butyraldehydebutyraldehyde results in increased expression of HLA-A mRNA26079696
D002220CarbamazepineHLA-A gene polymorphism affects the susceptibility to Carbamazepine21428769
D002220CarbamazepineHLA-A gene SNP affects the susceptibility to Carbamazepine16538176
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of HLA-A mRNA15963578
D002440CefoxitinCefoxitin affects the expression of HLA-A mRNA25811541
C030583ceric oxideceric oxide analog results in decreased expression of HLA-A mRNA24821434
C100187chloropicrinchloropicrin results in decreased expression of HLA-A mRNA26352163
D003907DexamethasoneDexamethasone results in decreased expression of HLA-A mRNA25047013
D002945CisplatinHLA-A protein affects the susceptibility to Cisplatin16217747
D002945Cisplatin[Piroxicam co-treated with Cisplatin] results in increased expression of HLA-A mRNA21858171
D004041Dietary Fats[Dietary Fats co-treated with resveratrol] results in decreased expression of HLA-A mRNA21852083
D004061DiflunisalDiflunisal affects the expression of HLA-A mRNA25811541
D004391DustDust results in increased expression of HLA-A mRNA17805423
C118739entinostatentinostat results in increased expression of HLA-A mRNA27188386
D004917ErythromycinErythromycin affects the expression of HLA-A mRNA25811541
D005047EtoposideEtoposide affects the expression of HLA-A mRNA25811541
D011345FenofibrateHLA-A gene polymorphism affects the susceptibility to Fenofibrate28043905
D005557FormaldehydeFormaldehyde results in increased expression of HLA-A mRNA18045764
D005557FormaldehydeFormaldehyde results in increased expression of HLA-A protein18045764
D017313FenretinideFenretinide results in decreased expression of HLA-A mRNA28973697
D017313FenretinideFenretinide results in increased expression of HLA-A mRNA28973697
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-A mRNA17183730
C492448ICG 001ICG 001 results in increased expression of HLA-A mRNA26191083
D007069IfosfamideIfosfamide affects the expression of HLA-A mRNA25811541
D020910KetorolacKetorolac affects the expression of HLA-A mRNA25811541
C045463leflunomideleflunomide affects the expression of HLA-A mRNA25811541
C482199lipopolysaccharide, E coli O55-B5"[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HLA-A mRNA"18930950
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of HLA-A mRNA22235868
D008727MethotrexateHLA-A protein affects the susceptibility to Methotrexate16217747
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of HLA-A mRNA24810058
D008911MinocyclineMinocycline affects the expression of HLA-A mRNA25811541
D010396PenicillamineHLA-A gene polymorphism affects the susceptibility to Penicillamine3459889
D010894Piroxicam[Piroxicam co-treated with Cisplatin] results in increased expression of HLA-A mRNA21858171
D011192Potassium DichromatePotassium Dichromate results in increased expression of HLA-A protein23718831
C030984pyrenepyrene results in decreased expression of HLA-A mRNA15963578
C012526quercitrinquercitrin affects the expression of HLA-A mRNA25193878
C059514resveratrol[Dietary Fats co-treated with resveratrol] results in decreased expression of HLA-A mRNA21852083
C017947sodium arsenitesodium arsenite results in decreased expression of HLA-A mRNA25879800
D018038Sodium SeleniteSodium Selenite results in increased expression of HLA-A mRNA18175754
C041359terbinafineHLA-A gene polymorphism affects the susceptibility to terbinafine28043905
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of HLA-A mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of HLA-A mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of HLA-A mRNA19619570
D013849ThimerosalThimerosal results in decreased expression of HLA-A mRNA27188386
D013988TiclopidineHLA-A gene polymorphism affects the susceptibility to Ticlopidine28043905
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of HLA-A mRNA28111298
C052342topiramatetopiramate affects the expression of HLA-A mRNA25811541
C080163trovafloxacin"[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HLA-A mRNA"18930950
D017974Uranium CompoundsUranium Compounds results in decreased expression of HLA-A mRNA19654044
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-A mRNA17183730
D014635Valproic AcidValproic Acid affects the expression of HLA-A mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of HLA-A mRNA19101580|2317975
D015215ZidovudineZidovudine affects the expression of HLA-A mRNA25811541
C088658zoledronic acidzoledronic acid results in increased expression of HLA-A mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-HDA22658674  
GO:0005102signaling receptor binding-IBA21873635  
GO:0005515protein binding-IPI23401559  
GO:0030881beta-2-microglobulin binding-IMP23566939  
GO:0030881beta-2-microglobulin binding-ISS-  
GO:0042605peptide antigen binding-IBA21873635  
GO:0042605peptide antigen binding-IMP23566939  
GO:0042605peptide antigen binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001916positive regulation of T cell mediated cytotoxicity-IBA21873635  
GO:0002474antigen processing and presentation of peptide antigen via MHC class I-IBA21873635  
GO:0002474antigen processing and presentation of peptide antigen via MHC class I-TAS-  
GO:0002476antigen processing and presentation of endogenous peptide antigen via MHC class Ib-IBA21873635  
GO:0002479antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent-TAS-  
GO:0002480antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent-TAS-  
GO:0006955immune response-IBA21873635  
GO:0016032viral process-IEA-  
GO:0050776regulation of immune response-TAS-  
GO:0060333interferon-gamma-mediated signaling pathway-TAS-  
GO:0060337type I interferon signaling pathway-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005783endoplasmic reticulum-ISS-  
GO:0005794Golgi apparatus-ISS-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-TAS-  
GO:0009986cell surface-ISS-  
GO:0012507ER to Golgi transport vesicle membrane-TAS-  
GO:0030670phagocytic vesicle membrane-TAS-  
GO:0031901early endosome membrane-TAS-  
GO:0042612MHC class I protein complex-ISS-  
GO:0055038recycling endosome membrane-TAS-  
GO:0071556integral component of lumenal side of endoplasmic reticulum membrane-TAS-  
KEGG ID KEGG Term
hsa04144Endocytosis
hsa04145Phagosome
hsa04514Cell adhesion molecules (CAMs)
hsa04612Antigen processing and presentation
hsa04650Natural killer cell mediated cytotoxicity
hsa04940Type I diabetes mellitus
hsa05320Autoimmune thyroid disease
hsa05330Allograft rejection
hsa05332Graft-versus-host disease
hsa05416Viral myocarditis
Reactome ID Reactome Term Evidence
R-HSA-1236974ER-Phagosome pathwayTAS
R-HSA-1236974ER-Phagosome pathwayIEA
R-HSA-1236975Antigen processing-Cross presentationTAS
R-HSA-1236975Antigen processing-Cross presentationIEA
R-HSA-1236977Endosomal/Vacuolar pathwayTAS
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1280218Adaptive Immune SystemIEA
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-168256Immune SystemIEA
R-HSA-198933Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-877300Interferon gamma signalingTAS
R-HSA-8852135Protein ubiquitinationTAS
R-HSA-8866654E3 ubiquitin ligases ubiquitinate target proteinsTAS
R-HSA-909733Interferon alpha/beta signalingTAS
R-HSA-913531Interferon SignalingTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationIEA
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS
R-HSA-983170Antigen Presentation: Folding, assembly and peptide loading of class I MHCIEA
R-HSA-983170Antigen Presentation: Folding, assembly and peptide loading of class I MHCTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
6983485Increased frequency of DR3 antigen in alcoholic hepatitis and cirrhosis. (1982 Oct)Bron BHepatogastroenterology
23395714Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. (2013 Aug)Sinkus MLBrain Behav Immun
23999606Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. (2014 Feb)Sundqvist EMult Scler
1956559Post-transplant erythrocytosis and immunosuppression with cyclosporin: a case-control study. (1991)Innes ANephrol Dial Transplant
1373340Do histocompatibility antigens influence the risk of head and neck carcinoma? (1992 May 1)Houck JRCancer
29343473Smoking affects the interferon beta treatment response in multiple sclerosis. (2018 Feb 13)Petersen ERNeurology
3108592Immunogenetic factors as determinants of asbestosis. (1987)Begin RLung
28597127The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement. (2017 Oct)Hedstrom AKEur J Epidemiol
8740767HLA*A2 confers mortality risk for cardiovascular disease in Pimans. (1996 Mar)Williams RCTissue Antigens
26339134HLA Haplotypes and Genotypes Frequencies in Brazilian Chronic Periodontitis Patients. (2015)Sippert EAMediators Inflamm
3476147No association between HLA antigens and adenocarcinoma of the lung in non-smoking Chinese women in Hong Kong. (1986 Oct)Lam WKBr J Dis Chest
25324153Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk. (2014 Dec)Hedstrom AKInt J Epidemiol
23990522Diabetes in first-degree family members: a predictor of type 2 diabetes in 159 nonscreening Alabama hemochromatosis probands with HFE C282Y homozygosity. (2014)Barton JCDiabetes Care
18589099HLA polymorphisms as incidence factor in the progression to end-stage renal disease in Brazilian patients awaiting kidney transplant. (2008 Jun)Crispim JCTransplant Proc
18501999HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. (2008 Jun 25)Lin HHVaccine
17212707Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease. (2007 Jan)Palikhe ATissue Antigens
24662416HLA-A( *)02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6. (2014 Jun)Engdahl EHum Immunol
22933744Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis. (2012 Sep 25)Sundqvist ENeurology
20501960HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women. (2010)Hosono SJ Epidemiol
28350079Effects of irradiation on human leukocyte antigen class I expression in human papillomavirus positive and negative base of tongue and mobile tongue squamous cell carcinoma cell lines. (2017 Mar 16)Haeggblom LInt J Oncol
18721275HLA-G polymorphism and transitional cell carcinoma of the bladder in a Brazilian population. (2008 Aug)Castelli ECTissue Antigens
26459151Smoking is a major preventable risk factor for multiple sclerosis. (2016 Jul)Hedstrom AKMult Scler
8129850Association between maternal-fetal HLA-DR relationships and fetal growth. (1993 Dec)Hoff CAm J Reprod Immunol
6585136HLA A, B and DR typing in idiopathic dilated cardiomyopathy: a search for immune response factors. (1984 May 1)Anderson JLAm J Cardiol
6708601A study of HLA antigens in alcoholism. (1984 Apr)Robertson DMMayo Clin Proc
17509091Are there common human leucocyte antigen associations in juvenile idiopathic arthritis and periodontitis? (2007 Jun)Reichert SJ Clin Periodontol